Ascendis Pharma A/S (NASDAQ:ASND) Sees Significant Growth in Short Interest

Ascendis Pharma A/S (NASDAQ:ASND) saw a significant growth in short interest in October. As of October 31st, there was short interest totalling 3,410,000 shares, a growth of 5.6% from the October 15th total of 3,230,000 shares. Based on an average daily volume of 634,100 shares, the short-interest ratio is currently 5.4 days.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. TD Cowen dropped their price target on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research report on Friday. JPMorgan Chase & Co. decreased their price objective on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a report on Wednesday, October 23rd. Cantor Fitzgerald restated an “overweight” rating and set a $170.00 price objective on shares of Ascendis Pharma A/S in a report on Friday. Citigroup raised their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Finally, The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and an average price target of $191.77.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several hedge funds have recently bought and sold shares of the stock. Westfield Capital Management Co. LP lifted its position in Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after purchasing an additional 170,942 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in Ascendis Pharma A/S by 5.8% during the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after purchasing an additional 229,995 shares during the last quarter. Janus Henderson Group PLC lifted its position in Ascendis Pharma A/S by 6.8% during the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after purchasing an additional 267,881 shares during the last quarter. Capital International Investors lifted its position in Ascendis Pharma A/S by 0.5% during the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock valued at $331,261,000 after purchasing an additional 10,044 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in Ascendis Pharma A/S by 9.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after purchasing an additional 155,971 shares during the last quarter.

Ascendis Pharma A/S Stock Up 1.8 %

ASND opened at $126.51 on Monday. The firm has a 50-day moving average price of $132.30 and a 200-day moving average price of $132.60. Ascendis Pharma A/S has a twelve month low of $90.13 and a twelve month high of $161.00. The company has a market capitalization of $7.67 billion, a price-to-earnings ratio of -15.66 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. On average, sell-side analysts expect that Ascendis Pharma A/S will post -7.3 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.